The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29

被引:266
|
作者
Young, James D. [1 ,2 ]
Yao, Sylvia Y. M. [1 ,2 ]
Baldwin, Jocelyn M. [5 ]
Cass, Carol E. [1 ,3 ,4 ]
Baldwin, Stephen A. [5 ]
机构
[1] Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada
[2] Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada
[3] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada
[4] Cross Canc Inst, Edmonton, AB T6G 2H7, Canada
[5] Univ Leeds, Astbury Ctr Struct Mol Biol, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England
基金
加拿大健康研究院; 英国医学研究理事会; 加拿大自然科学与工程研究理事会; 瑞士国家科学基金会; 英国惠康基金;
关键词
Adenosine; Cancer; SLC28; SLC29; CNT; ENT; MEMBRANE MONOAMINE TRANSPORTER; FUNCTIONAL-CHARACTERIZATION; ADENOSINE TRANSPORT; MOLECULAR-CLONING; GENETIC-VARIANTS; EXPRESSION; NA+; POLYMORPHISMS; GEMCITABINE; HENT1;
D O I
10.1016/j.mam.2012.05.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nucleoside transport in humans is mediated by members of two unrelated protein families, the SLC28 family of cation-linked concentrative nucleoside transporters (CNTs) and the SLC29 family of energy-independent, equilibrative nucleoside transporters (ENTs). These families contain three and four members, respectively, which differ both in the stoichiometry of cation coupling and in permeant selectivity. Together, they play key roles in nucleoside and nucleobase uptake for salvage pathways of nucleotide synthesis. Moreover, they facilitate cellular uptake of several nucleoside and nucleobase drugs used in cancer chemotherapy and treatment of viral infections. Thus, the transporter content of target cells can represent a key determinant of the response to treatment. In addition, by regulating the concentration of adenosine available to cell surface receptors, nucleoside transporters modulate many physiological processes ranging from neurotransmission to cardiovascular activity. This review describes the molecular and functional properties of the two transporter families, with a particular focus on their physiological roles in humans and relevance to disease treatment. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:529 / 547
页数:19
相关论文
共 50 条
  • [31] Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1
    Vlachodimou, Anna
    IJzerman, Adriaan P.
    Heitman, Laura H.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [32] Equilibrative Nucleoside Transporter 1 (ENT1, SLC29A1) Facilitates Transfer of the Antiretroviral Drug Abacavir across the Placenta
    Cerveny, Lukas
    Ptackova, Zuzana
    Ceckova, Martina
    Karahoda, Rona
    Karbanova, Sara
    Jiraskova, Lucie
    Greenwood, Susan L.
    Glazier, Jocelyn D.
    Staud, Frantisek
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (11) : 1817 - 1826
  • [33] Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
    Marechal, Raphael
    Mackey, John R.
    Lai, Raymond
    Demetter, Pieter
    Peeters, Marc
    Polus, Marc
    Cass, Carol E.
    Young, James
    Salmon, Isabelle
    Deviere, Jacques
    Van Laethem, Jean-Luc
    CLINICAL CANCER RESEARCH, 2009, 15 (08) : 2913 - 2919
  • [34] Equilibrative nucleotide transporter ENT3 (SLC29A3): A unique transporter for inherited disorders and cancers
    Ma, Hongying
    Qu, Jian
    Liao, Yongkang
    Liu, Linxin
    Yan, Min
    Wei, Yiwen
    Xu, Weixin
    Luo, Jian
    Dai, Yuxin
    Pang, Zicheng
    Qu, Qiang
    EXPERIMENTAL CELL RESEARCH, 2024, 434 (02)
  • [35] A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum
    Errasti-Murugarren, Ekaitz
    Molina-Arcas, Miriam
    Casado, Fco Javier
    Pastor-Anglada, Marcal
    FASEB JOURNAL, 2009, 23 (01): : 172 - 182
  • [36] NUCLEOSIDE TRANSPORTER SLC28A2/3 AND SLC29A1/2 GENETICS: PROTECTION AGAINST ANAEMIA IN CHRONIC HEPATITIS C PATIENTS RECEIVING RIBAVIRIN
    Hofmann, W. P.
    Doehring, A.
    Schlecker, C.
    Zeuzem, S.
    Sarrazin, C.
    Berg, T.
    Mueller, T.
    Herrmann, E.
    Geisslinger, G.
    Loetsch, J.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S457 - S457
  • [37] Expression of Concentrative Nucleoside Transporters (SLC28A) in the Human Placenta: Effects of Gestation Age and Prototype Differentiation-Affecting Agents
    Jiraskova, Lucie
    Cerveny, Lukas
    Karbanova, Sara
    Ptackova, Zuzana
    Staud, Frantisek
    MOLECULAR PHARMACEUTICS, 2018, 15 (07) : 2732 - 2741
  • [38] EXPRESSION OF CONCENTRATIVE NUCLEOSIDE TRANSPORTERS (SLC28A) IN THE HUMAN PLACENTA; EFFECTS OF GESTATION AGE AND PROTOTYPE DIFFERENTIATION-AFFECTING AGENTS
    Jiraskova, Lucie
    Karbanova, Sara
    Ptackova, Zuzana
    Staud, Frantisek
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S73 - S73
  • [39] Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines
    Fotoohi, AK
    Lindqvist, M
    Peterson, C
    Albertioni, F
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 343 (01) : 208 - 215
  • [40] ROLE OF NUCLEOSIDE TRANSPORTER SLC28A2/3 AND SLC29A1/2 GENETICS IN RIBAVIRIN THERAPY: PROTECTION AGAINST ANAEMIA IN CHRONIC HEPATITIS C PATIENTS
    Hofmann, Wolf P.
    Doehring, Alexandra
    Schlecker, Christina
    Zeuzem, Stefan
    Sarrazin, Christoph
    Berg, Thomas
    Mueller, Tobias
    Herrmann, Eva
    Loetsch, Joern
    HEPATOLOGY, 2010, 52 (04) : 760A - 760A